Stay updated on First-Line Tarlatamab Combo in ES-SCLC Clinical Trial

Sign up to get notified when there's something new on the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The differences are minor UI and formatting adjustments to the Study Details page without changes to core study data such as eligibility criteria, primary outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-03T01:32:51.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    Minor metadata update: the citation’s online-ahead-of-print note and date formatting were adjusted; core study information remains the same.
    Difference
    0.6%
    Check dated 2025-10-19T16:36:12.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    Core content updated with a government funding notice and updated operating-status guidance; version updated from v3.1.0 to v3.2.0.
    Difference
    3%
    Check dated 2025-10-05T10:34:06.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    Upgrade version from v3.0.2 to v3.1.0. No other content changes are specified.
    Difference
    0.1%
    Check dated 2025-09-28T03:22:00.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    Added a new Publications entry detailing a Lancet Oncology study (DeLLphi-303) on tarlatamab with a PD-L1 inhibitor as maintenance therapy in extensive-stage SCLC; no deletions were present.
    Difference
    4%
    Check dated 2025-09-20T22:14:59.000Z thumbnail image
  8. Check
    60 days ago
    Change Detected
    Summary
    Version tag updated from v3.0.1 to v3.0.2; the old tag was removed and the 'Back to Top' link was deleted.
    Difference
    0.2%
    Check dated 2025-09-13T17:42:34.000Z thumbnail image

Stay in the know with updates to First-Line Tarlatamab Combo in ES-SCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page.